AVEO Pharmaceuticals, Inc. (AVEO)
-NasdaqGS 2.71 
0.01(0.37%) May 24, 4:00PM EDT|After Hours
:
2.75 0.04 (1.48%) May 24, 6:17PM EDT
| Prev Close: | 2.70 |
|---|
| Open: | 2.33 |
|---|
| Bid: | 2.56 x 200 |
|---|
| Ask: | 2.82 x 100 |
|---|
| 1y Target Est: | 3.25 |
|---|
| Beta: | 0.86 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 2.29 - 2.71 |
|---|
| 52wk Range: | 2.25 - 14.08 |
|---|
| Volume: | 3,462,710 |
|---|
| Avg Vol (3m): | 2,034,790 |
|---|
| Market Cap: | 138.95M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.57 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Most U.S. Stocks Fall as Investors Weigh Data, Stimulusat Bloomberg(Fri, May 24)
- Aveo slumps as Astellas pares cancer drug supportAP(Fri, May 24)
- Aveo says partner Astellas will not seek EU nod for kidney cancer drugat Reuters(Thu, May 23)
- AVEO PHARMACEUTICALS INC Files SEC form 8-K, Other EventsEDGAR Online(Thu, May 23)
- Life Science Industry Veteran Stephane Bancel Joins Flagship VenturesPR Newswire(Wed, May 22)
- Law Offices of Todd M. Garber Announces Investigation of AVEO Pharmaceuticals, Inc.Business Wire(Mon, May 20)
- Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Aveo Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -- AVEOGlobeNewswire(Fri, May 17)
- Aveo Pharmaceuticals, Inc. Sued by InvestorPR Newswire(Fri, May 17)
- AVEO PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Fri, May 17)
- AVEO and Astellas Announce Presentations of Tivozanib Clinical Data at 2013 American Society of Clinical Oncology Annual MeetingBusiness Wire(Wed, May 15)
- Complete Seth Klarman And Baupost Group Portfolio Updateat Seeking Alpha(Wed, May 15)
- Aveo Screwed Up but Its Kidney Cancer Drug Is Realat TheStreet(Wed, May 15)
- Tracking Seth Klarman's Baupost Group Holdings - Q1 2013 Updateat Seeking Alpha(Wed, May 15)
- Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against AVEO Pharmaceuticals, Inc.Business Wire(Tue, May 14)
- The Law Offices of Marc S. Henzel Announces Class Action Lawsuit Against Aveo Pharmaceuticals, Inc. and Certain Officers -- (Nasdaq: AVEO) was filed on behalf of stockholdersPR Newswire(Tue, May 14)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 7.38 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.35 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.57 |
|---|
| Mean Recommendation*: | 3.1 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
AVEO Pharmaceuticals, Inc., doing business as AVEO Oncology, operates as a cancer therapeutics company. The company engages in discovering, developing, and commercializing targeted cancer therapies using its Human Response Platform.
View More